JosephASparanoMD

Breast Cancer

Ezra M Greenspan MD Professor of Clinical Cancer Therapeutics; Chief, Division of Hematology and Medical Oncology; Deputy Director, Tisch Cancer Institute; Icahn School of Medicine at Mount Sinai, NY, NY

Join to view full profile

Dr. Sparano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sparano's full profile

Already have an account?

Office
1425 Madison Avenue
New York, NY 10029
Phone+1 212-659-6754

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1986 - 1987
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine, 1982 - 1985
New York Medical CollegeClass of 1982

Certifications & Licensure

NY State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2002, 2006, 2018
Top Doctors: New York Metro Area Castle Connolly, 2003-2008, 2010-2014
Super Doctor SuperDoctors.com

Clinical Trials

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy Start of enrollment: 1997 Dec 02
Completed
Phase 3
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes Start of enrollment: 1999 Nov 16
Completed
Phase 3
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 2003 Mar 01
Completed
Phase 2
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 2003 Feb 01
Completed
Phase 2
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Start of enrollment: 2007 Feb 28
Completed
Phase 2
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Start of enrollment: 2006 Sep 01
Completed
Phase 2
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 1, Phase 2
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 1, Phase 2
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy Start of enrollment: 2007 Dec 01
Completed
Phase 1, Phase 2
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy Start of enrollment: 2005 Oct 07
Completed
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Start of enrollment: 2010 May 26
Completed
Phase 2
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 1
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Start of enrollment: 2010 Jun 30
Active, not recruiting
Phase 2
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Start of enrollment: 2010 Nov 16
Completed
Phase 1
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Apr 21
Active, not recruiting
Phase 2
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
Active, not recruiting
Phase 1
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Start of enrollment: 2012 Aug 31
Active, not recruiting
Phase 1
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Start of enrollment: 2012 Jan 01
Terminated
Phase 1, Phase 2
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer Start of enrollment: 2013 Jun 01
Active, not recruiting
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Endocrine Response in Women With Invasive Lobular Breast Cancer Start of enrollment: 2015 Sep 30
Active, not recruiting
Phase 2
Roles: Contact
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer Start of enrollment: 2018 Dec 12
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

1318 citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert Gray, Della F. Makower, Kathleen I. Pritchard, Kathy S. Albain
The New England Journal of Medicine. 2018-06-03
89 citations
Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial
Joseph A. Sparano, Molin Wang, Fengmin Zhao, Vered Stearns, Silvana Martino
Journal of the National Cancer Institute. 2012-03-07
69 citations
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Kathy S. Albain, Robert Gray, Della F. Makower, Amir Faghih, Daniel F. Hayes
Journal of the National Cancer Institute. 2021-04-06

Journal Articles

Deconstructing Racial and Ethnic Disparities in Breast Cancer
Joseph A Sparano, Otis W Brawley, JAMA Oncology
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Abstracts/Posters

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
Joseph Sparano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
Joseph Sparano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
2019 ASCO Annual Meeting - 6/1/2019
Selected Updates in Breast Cancer
2007 Annual Meeting, Chicago, Illinois, USA

Press Mentions

TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients with Early-Stage Breast CancerDecember 13th, 2022
SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without ChemoDecember 12th, 2022
Global Cardio-Oncology Viewpoints ‘Contextualize’ ESC GuidelinesDecember 12th, 2022
Join now to see all

Grant Support

Albert Einstein Core SiteNational Cancer Institute2010–2011
Centralized Protocol And Data Management UnitNational Cancer Institute2007–2011
Eastern Cooperative Oncology GroupNational Cancer Institute2004–2011
Montefiore Medical Center / Albert Einstein School Of MedicineNational Cancer Institute2006
AIDS Malignancy ConsortiumNational Cancer Institute1999–2005
Eastern Cooperative Oncology GroupNational Cancer Institute2002–2003